Phase II trial of dose dense paclitaxel plus carboplatin in advanced or recurrent uterine corpus cancer
Not Applicable
- Conditions
- Advanced or recurrent uterine corpus cancer
- Registration Number
- JPRN-UMIN000017138
- Lead Sponsor
- Kansai Clinical Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 48
Inclusion Criteria
Not provided
Exclusion Criteria
1)motor or sensory neuropathy with dysfunction 2) alcoholic hypersensitivity 3)bacterial infection to needtreatment 4) myocardial infarction within 6 months 5) unstable angina 6) poor control diabetes 7) active multiple malignancy 8) Interstitial pneumonia, pulmonary fibrosis 9) Paclitaxel or CBDCA is contra-indicated. 10) HBs-Ag(+) 11) Paralytic or mechanical bowel obstruction 12) History of severe drug-induced hypersensitivity syndrome 13) Any other cases who are regarded as inadequate for study enrollment by investigators.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method response rate
- Secondary Outcome Measures
Name Time Method